|
|
 |
[2026/02/03] |
 |
|
 |
 |

±¹³»Æ¯Çã µî·Ï !! |
 |
|
|
¹ß¸íÀÇ ¸íĪ: ÆÄŬ¸®Å¹¼¿¿¡ ´ëÇÏ¿© ³»¼ºÀ» °®´Â ³¼Ò¾ÏÀÇ Áø´ÜÀ» À§ÇÑ ºÐ¼®¹æ¹ý
Ãâ¿øÀÏ: 2022.09.22
µî·ÏÀÏ: 2026.01.29
Ãâ¿ø¹øÈ£: 10-2022-0120030
µî·Ï¹øÈ£: 10-2921994 |
|
|
|
|
 |
[2025/11/28] |
 |
|
 |
 |

±¹³»Æ¯Çã µî·Ï !! |
 |
|
|
¹ß¸íÀÇ ¸íĪ: ½Ã½ºÇÃ¶óÆ¾¿¡ ´ëÇÏ¿© ³»¼ºÀ» °®´Â ³¼Ò¾ÏÀÇ Áø´ÜÀ» À§ÇÑ ºÐ¼®¹æ¹ý
Ãâ¿øÀÏ: 2022.07.29
µî·ÏÀÏ: 2025.11.19
Ãâ¿ø¹øÈ£: 10-2022-0094364
µî·Ï¹øÈ£: 10-2889839 |
|
|
|
|
 |
[2025/10/21] |
 |
|
 |
 |

Manuscript Accepted !! |
 |
|
|
³í¹®Á¦¸ñ: Deubiquitomic and bioinformatic analyses in cisplatin-treated lung cancer cells.
Àú³Î: Int. J. Med. Sci. (2024 Impact factor: 3.2) |
|
|
|
|
 |
[2025/10/21] |
 |
|
 |
 |

Manuscript Accepted !! |
 |
|
|
³í¹®Á¦¸ñ: Single-cell RNA sequence analysis reveals USP32 as a therapeutic target to mitigate PD-L1-driven colorectal tumorigenesis in vitro and in vivo.
Àú³Î: Theranostics (2024 Impact factor: 13.3) |
|
|
|
|
 |
[2025/09/29] |
 |
|
 |
 |

ÀÇ»ý¸í°úÇаú ÇмúÁ¦¿¡¼ ¿ì¼ö»ó ¼ö»ó ! |
 |
|
|
| ÃÖ¹Ì¼Ò¿Í ÇÑ´Ù¿µ ÇлýÀÌ ÀÇ»ý¸í°úÇаú ÇмúÁ¦¿¡¼ ¿ì¼ö»ó ¼ö»ó ~ |
|
|
|
|
|